HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1)

P3, N=88, Not yet recruiting, Takeda

P2, N=92, Recruiting, Chugai Pharmaceutical | Not yet recruiting --> Recruiting

Despite similar clinical presentations, idiopathic and paraneoplastic OMASs appear to have distinct immunopathogenic mechanisms. In paraneoplastic OMAS, enrichment of specific HLA antigens and convergent TCR profiles supports antigen-driven T cell-mediated autoimmunity.

This study reveals that a B cell subpopulation characterized by the co-expression of HLA-DRB5, HLA-DQA2, HLA-DQB1, CD74, and ACTG1 is significantly associated with nCRT response in rectal cancer. These findings offer actionable insights for optimizing clinical treatment strategies, including patient stratification and personalized therapy selection.

CYP27A1 is implicated as a suppressor of LUAD brain metastasis via ferroptosis. The six-gene model facilitates risk stratification, and macrophage-driven microenvironment remodelling informs potential immunotherapy strategies, advancing LUAD precision oncology.

In 9 patients with myositis and myocarditis, the frequency of HLA-B*52:01 locus was higher than that in the normal population. Our research findings reveal that patients carrying autoimmune susceptibility genes have a higher risk of developing irAEs when treated with ICI, specific HLA alleles may be associated with the risk of ICI-related MG/myositis/myocarditis, but further large-scale, multi-center validation is needed.

This study identifies m6A-related SNPs as important regulatory factors shared between OC and EM. By integrating genetic, transcriptomic, and functional data, we highlight immune and metabolic pathways-especially those involving LDHB, IFITM2, and HLA-DQB1-as key contributors to cisplatin resistance. These findings provide potential therapeutic targets and a framework for understanding m6A-associated mechanisms in ovarian cancer progression. Further in vivo studies are needed to validate the direct effects of specific m6A-SNPs.

This study elucidates genes in NSCLC that are highly associated with both disease progression and type II pneumocyte features as potential biomarkers of NSCLC, and predicts their potential regulatory functions as well as their impact on the immune infiltration profile of NSCLC, providing guidance for the unraveling of the immune mechanisms of NSCLC.

qRT-PCR and Western blot confirmed PTPRF, ULK1, TGM3, and CRABP2 were upregulated at both the mRNA and protein levels. These findings indicate that the Treg-related signature serves as robust prognostic biomarkers and may guide personalized immunotherapy in SCKM.

P2, N=56, Active, not recruiting, Center for International Blood and Marrow Transplant Research | Recruiting --> Active, not recruiting | Trial completion date: Aug 2030 --> Dec 2028 | Trial primary completion date: Aug 2029 --> Dec 2027

Among 289 patients with clinical follow-up, HLA-DQB1*06:04 (aHR [95% CI] = 3.71 [1.57-8.77]) and DRB1*13:02 (aHR = 3.95 [1.77-8.81]) were associated with faster MR4 achievement in imatinib-treated patients (FDR < 0.01), while B*44:02 (aHR = 4.83 [1.62-14.41]) predicted favorable response to dasatinib (FDR < 0.05). Conversely, a higher HED score for HLA-C was associated with improved TFR in dasatinib-treated patients (P = 0.0067). These findings suggest that HLA genotype and class-specific HED may influence CML susceptibility and outcomes and could inform TKI selection and discontinuation strategies.

Hair thickness remained significantly lower in the tamoxifen monotherapy. These findings suggest that tamoxifen may impair follicular recovery after chemotherapy, highlighting the importance of individualized counseling and close dermatologic follow-up in patients undergoing scalp cooling.